CARsgen Granted US Orphan Drug Status for Claudin18.2 CAR-T Drug
October 05, 2020 at 05:58 AM EDT
Shanghai 's CARsgen Therapeutics was granted orphan drug designation in the US for its anti-claudin18.2 autologous CAR-T candidate in patients with gastric and gastroesophageal junction adenocarcinoma. Previously, CARsgen was awarded orphan drug status in China . CT041 is the first claudin18.2-targeted CAR T-cell approved to start trials in the US and the first in China as well. A Phase Ib trial of the candidatel is underway for patients with advanced gastric, gastroesophageal or pancreatic adenocarcinoma. More details.... Share this with colleagues: // //
